Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...
The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results